486 related articles for article (PubMed ID: 27844213)
1. B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
Kinzel S; Weber MS
CNS Drugs; 2016 Dec; 30(12):1137-1148. PubMed ID: 27844213
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.
Lehmann-Horn K; Kinzel S; Weber MS
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946620
[TBL] [Abstract][Full Text] [Related]
3. CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?
Agahozo MC; Peferoen L; Baker D; Amor S
Mult Scler Relat Disord; 2016 Sep; 9():110-7. PubMed ID: 27645355
[TBL] [Abstract][Full Text] [Related]
4. Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
Chen D; Ireland SJ; Davis LS; Kong X; Stowe AM; Wang Y; White WI; Herbst R; Monson NL
J Immunol; 2016 Feb; 196(4):1541-9. PubMed ID: 26764035
[TBL] [Abstract][Full Text] [Related]
5. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
6. [Targeting B cells in multiple sclerosis. Current concepts and strategies].
Menge T; Büdingen HC; Dalakas MC; Kieseier BC; Hartung HP
Nervenarzt; 2009 Feb; 80(2):190-8. PubMed ID: 19189075
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
Sellebjerg F; Blinkenberg M; Sorensen PS
CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
[TBL] [Abstract][Full Text] [Related]
8. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
Gasperini C; Haggiag S; Ruggieri S
Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
[TBL] [Abstract][Full Text] [Related]
9. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
10. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives.
D'Amico E; Zanghì A; Gastaldi M; Patti F; Zappia M; Franciotta D
Autoimmun Rev; 2019 Jul; 18(7):665-672. PubMed ID: 31059839
[TBL] [Abstract][Full Text] [Related]
11. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
Ancau M; Berthele A; Hemmer B
Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
[TBL] [Abstract][Full Text] [Related]
12. The role of antibodies in multiple sclerosis.
Weber MS; Hemmer B; Cepok S
Biochim Biophys Acta; 2011 Feb; 1812(2):239-45. PubMed ID: 20600871
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
[TBL] [Abstract][Full Text] [Related]
14. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
15. Development of anti-CD20 therapy for multiple sclerosis.
Bartok B; Silverman GJ
Exp Cell Res; 2011 May; 317(9):1312-8. PubMed ID: 21510932
[TBL] [Abstract][Full Text] [Related]
16. The role of B cells in multiple sclerosis: implications for B-cell-targeted therapy.
Hirotani M; Niino M; Sasaki H
Curr Med Chem; 2010; 17(28):3215-22. PubMed ID: 20666723
[TBL] [Abstract][Full Text] [Related]
17. Single-cell profiling indicates a high similarity between immune cells in the cerebrospinal fluid and in meningeal ectopic lymphoid tissue in experimental autoimmune encephalomyelitis.
Georgieva T; Diddens J; Friedrich V; Lepennetier G; Brand RM; Lehmann-Horn K
Front Immunol; 2024; 15():1400641. PubMed ID: 38933267
[TBL] [Abstract][Full Text] [Related]
18. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategies targeting B-cells in multiple sclerosis.
Milo R
Autoimmun Rev; 2016 Jul; 15(7):714-8. PubMed ID: 26970489
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 monoclonal antibodies in multiple sclerosis.
Moreno Torres I; García-Merino A
Expert Rev Neurother; 2017 Apr; 17(4):359-371. PubMed ID: 27718747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
